Cell Genesys Invites You to Join Its Company Presentation At the JPMorgan H & Q Healthcare Conference on the Web
NEW YORK, Jan. 7 /PRNewswire/ -- In conjunction with Cell Genesys' (Nasdaq: CEGE - news) company presentation at the JPMorgan H & Q Healthcare Conference, you are invited to listen to the presentation that will be broadcast live over the Internet on Tuesday, January 8, 2002, at 11:00 a.m. EST with Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys.
What: Cell Genesys Company Update
JPMorgan H & Q Healthcare Conference
When: Tuesday, January 8, 2002, at 11:00 a.m. EST
Where: www.cellgenesys.com
How: Live over the Internet -- Simply log on to the web at the
address above
Cell Genesys, which is headquartered in Foster City, CA, is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms-GVAX® cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870 in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products company. For additional information, please visit the company's website at www.cellgenesys.com.
If you are unable to participate during the live webcast, the call will be archived on www.cellgenesys.com within 12 hours following the presentation and will be available for two weeks. To access the replay, go to the Investor Relations section of the site.
CONTACT: Jennifer Cook Williams of Cell Genesys, Inc., +1-650-425-4542.
SOURCE: Cell Genesys, Inc. |
